Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07496567 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
A Phase 2 study, sponsored by EyeBiotech.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 960
- Enrollment target
NCT07496567: Recruiting Phase 2 study, sponsored by EyeBiotech.
NCT07496567 is a Phase 2 study that is actively recruiting participants, run by EyeBiotech. The registered enrollment target is 960 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (622% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07496567, a Phase 2 study, is actively recruiting participants, sponsored by EyeBiotech.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 960 participants
- Enrollment target
Study Summary
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD. The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.
Primary Outcome
Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to Year 1 will be assessed.
Interventions
- DRUG Aflibercept
- DRUG Tiespectus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 960 participants |
| Start Date | 2026-04-15 |
| Est. Completion | 2028-07-31 |
| Phase | Phase 2 |
What NCT07496567 shows while recruiting
NCT07496567 is an interventional study that assigns participants to a tested intervention. The registered 960 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (622% higher).
The record links to 0 conditions, and to 2 interventions - of which Aflibercept is the first listed.
NCT07496567 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07496567 about?
NCT07496567 is a clinical study titled "A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)". Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) ca...
What is the current status of trial NCT07496567?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 960 participants. The study started on 2026-04-15. Estimated completion is 2028-07-31.
What interventions are being tested in trial NCT07496567?
The interventions under investigation include: Aflibercept (DRUG), Tiespectus (DRUG).
Who is sponsoring clinical trial NCT07496567?
This trial is sponsored by EyeBiotech, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07496567's enrollment target sits among peer trials
960 28th of 2000 higher than 1,972 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04726241 · 960 participants · Phase 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- NCT05142384 · 960 participants · NA
ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start
- NCT05178498 · 960 participants
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
- NCT05946629 · 960 participants · NA
SELUTION 4 De Novo Small Vessel IDE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI